Sagimet Biosciences (SGMT) Liabilities and Shareholders Equity (2022 - 2026)

Sagimet Biosciences' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $107.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 26.28% year-over-year to $107.8 million; the TTM figure through Mar 2026 stood at $490.0 million (down 26.88% YoY), while the FY2025 annual figure was $116.5 million, down 27.32% from the prior year.
• Liabilities and Shareholders Equity was $107.8 million for Q1 2026 at Sagimet Biosciences, down from $116.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $194.5 million in Q1 2024 to a low of $21.5 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $123.8 million across 5 years, with a median of $128.4 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 779.24% in 2024, then retreated 27.32% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $33.0 million in 2022, then jumped by 192.81% to $96.7 million in 2023, then soared by 65.7% to $160.3 million in 2024, then declined by 27.32% to $116.5 million in 2025, then retreated by 7.49% to $107.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $107.8 million (Q1 2026), $116.5 million (Q4 2025), and $128.4 million (Q3 2025), per Business Quant data.